Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia
Clinical trial NCT06004856 · UNKNOWN
Trial details
- NCT number
- NCT06004856
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-26
- Primary completion
- 2025-12-31
- Enrollment
- 195
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.